From genotype to phenotype in Dravet disease

Area of Science:

• Neuroscience
• Genetics
• Pediatric Neurology

Background:

• Dravet syndrome presents with severe epilepsy starting in infancy, often triggered by fever.
• It progresses to include various seizure types and significant non-epileptic developmental challenges.
• Sudden Unexpected Death in Epilepsy (SUDEP) has a high incidence across all age groups.

Purpose of the Study:

• To comprehensively review the clinical spectrum, pathophysiology, and management of Dravet syndrome.
• To highlight the genetic basis, SCN1A haploinsufficiency and NaV1.1 dysfunction, underlying the syndrome's diverse manifestations.
• To discuss current and potential therapeutic strategies.

Main Methods:

• Literature review of Dravet syndrome, focusing on clinical presentation, genetic etiology, and treatment outcomes.
• Analysis of the role of SCN1A mutations and NaV1.1 channel dysfunction in neuronal circuits.
• Synthesis of information on antiepileptic drugs, ketogenic diet, and emerging therapies.

Main Results:

• Dravet syndrome exhibits a wide range of seizures and progressive non-epileptic features including intellectual disability, ataxia, and gait disturbances.
• SCN1A haploinsufficiency leads to NaV1.1 dysfunction, primarily affecting GABAergic interneurons, explaining epilepsy and other neurological deficits.
• Certain antiepileptic drugs (sodium channel blockers) can exacerbate symptoms, while others (valproate, stiripentol) and ketogenic diet show efficacy.

Conclusions:

• Dravet syndrome is a complex neurodevelopmental disorder caused by SCN1A mutations, extending beyond epilepsy.
• Targeting the underlying NaV1.1 dysfunction is crucial for improving both epileptic and non-epileptic manifestations.
• A tailored therapeutic approach, avoiding specific drug classes and considering the ketogenic diet, is essential for management.